293 related articles for article (PubMed ID: 24096380)
21. NK cells: innate immunity against hematological malignancies?
Costello RT; Fauriat C; Sivori S; Marcenaro E; Olive D
Trends Immunol; 2004 Jun; 25(6):328-33. PubMed ID: 15145323
[TBL] [Abstract][Full Text] [Related]
22. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD.
Bishara A; De Santis D; Witt CC; Brautbar C; Christiansen FT; Or R; Nagler A; Slavin S
Tissue Antigens; 2004 Mar; 63(3):204-11. PubMed ID: 14989709
[TBL] [Abstract][Full Text] [Related]
23. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
[TBL] [Abstract][Full Text] [Related]
24. Genomic polymorphisms of the innate immune system and allogeneic stem cell transplantation.
MartÃn-Antonio B; Granell M; Urbano-Ispizua A
Expert Rev Hematol; 2010 Aug; 3(4):411-27. PubMed ID: 21083033
[TBL] [Abstract][Full Text] [Related]
25. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
Jones SC; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
[TBL] [Abstract][Full Text] [Related]
26. Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation.
Rezvani AR; Storb RF
J Autoimmun; 2008 May; 30(3):172-9. PubMed ID: 18242060
[TBL] [Abstract][Full Text] [Related]
27. Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation.
Clausen J; Wolf D; Petzer AL; Gunsilius E; Schumacher P; Kircher B; Gastl G; Nachbaur D
Clin Exp Immunol; 2007 Jun; 148(3):520-8. PubMed ID: 17493020
[TBL] [Abstract][Full Text] [Related]
28. T-cell therapy after hematopoietic stem cell transplantation.
Kennedy-Nasser AA; Brenner MK
Curr Opin Hematol; 2007 Nov; 14(6):616-24. PubMed ID: 17898565
[TBL] [Abstract][Full Text] [Related]
29. Related HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: observations of a single Chinese center.
Huang X; Liu D
Clin Transpl; 2011; ():237-45. PubMed ID: 22755417
[TBL] [Abstract][Full Text] [Related]
30. [Experimental study on IL-2- and IL-15 application in allogeneic hematopoietic stem cell transplantation].
Chen GH; Wu DP; Sun AN; Yang MZ; Wang Y; Tang XW; Chang HR; Feng YF; Zhu ZL
Zhonghua Xue Ye Xue Za Zhi; 2008 Aug; 29(8):526-30. PubMed ID: 19112915
[TBL] [Abstract][Full Text] [Related]
31. Natural-killer-cell-based treatment in haematopoietic stem-cell transplantation.
Passweg JR; Koehl U; Uharek L; Meyer-Monard S; Tichelli A
Best Pract Res Clin Haematol; 2006; 19(4):811-24. PubMed ID: 16997185
[TBL] [Abstract][Full Text] [Related]
32. Rapid immune reconstitution after a reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric refractory haematological malignancies.
Chen X; Hale GA; Barfield R; Benaim E; Leung WH; Knowles J; Horwitz EM; Woodard P; Kasow K; Yusuf U; Behm FG; Hayden RT; Shurtleff SA; Turner V; Srivastava DK; Handgretinger R
Br J Haematol; 2006 Nov; 135(4):524-32. PubMed ID: 17010105
[TBL] [Abstract][Full Text] [Related]
33. Activating killer immunoglobulin-like receptor incompatibilities enhance graft-versus-host disease and affect survival after allogeneic hematopoietic stem cell transplantation.
Giebel S; Nowak I; Dziaczkowska J; Czerw T; Wojnar J; Krawczyk-Kulis M; Holowiecki J; Holowiecka-Goral A; Markiewicz M; Kopera M; Karolczyk A; Kyrcz-Krzemien S; Kusnierczyk P
Eur J Haematol; 2009 Oct; 83(4):343-56. PubMed ID: 19500138
[TBL] [Abstract][Full Text] [Related]
34. [Role of NK cells in allogeneic hematopoietic stem cell transplantation--review].
Li XH; Gao CJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Aug; 14(4):845-8. PubMed ID: 16928336
[TBL] [Abstract][Full Text] [Related]
35. NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation.
Ruggeri L; Mancusi A; Burchielli E; Capanni M; Carotti A; Aloisi T; Aversa F; Martelli MF; Velardi A
Blood Cells Mol Dis; 2008; 40(1):84-90. PubMed ID: 17964828
[TBL] [Abstract][Full Text] [Related]
36. Adoptive Immunotherapies After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies.
Xiong Y; Bensoussan D; Decot V
Transfus Med Rev; 2015 Oct; 29(4):259-67. PubMed ID: 26282736
[TBL] [Abstract][Full Text] [Related]
37. [Alloreactive donor lymphocytes (DLI) after allogeneic hematopoietic stem cell transplantation (HSCT): study of toxicity and efficacy].
Michallet AS; Nicolini F; Michallet M
Bull Cancer; 2003; 90(8-9):758-62. PubMed ID: 14609766
[TBL] [Abstract][Full Text] [Related]
38. [Role of alloreactive natural killer cell in mouse MHC haploidentical bone marrow transplantation].
He Y; Wang HH; Wang M; Zhou Z; Zhai WJ; Huang Y; Jiang EL; Wang ZD; Zhou SY; Liu QG; Feng SZ; Han MZ
Zhonghua Xue Ye Xue Za Zhi; 2006 Feb; 27(2):82-6. PubMed ID: 16732957
[TBL] [Abstract][Full Text] [Related]
39. Suppression of graft-versus-host disease after adoptive infusion of alloreactive NK cells induced by silencing Ly49C gene in mice.
Cao D; Hu L; Wang Y; Wang L; Zheng W; Ma W
Transpl Immunol; 2009 Mar; 20(4):243-8. PubMed ID: 19010415
[TBL] [Abstract][Full Text] [Related]
40. Alloreactive natural killer cells in hematopoietic stem cell transplantation.
Pegram HJ; Ritchie DS; Smyth MJ; Wiernik A; Prince HM; Darcy PK; Kershaw MH
Leuk Res; 2011 Jan; 35(1):14-21. PubMed ID: 20719383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
